Literature DB >> 26924121

Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen.

Yousef Amini1, Majid Tebianian2, Nader Mosavari2, Mahdi Fasihi Ramandi3, Seyyd Mahmoud Ebrahimi4, Hamid Najminejad5, Mehran Dabaghian4, Meghdad Abdollahpour6.   

Abstract

Introduction The early secreted antigenic target 6-kDa protein (ESAT-6) plays an important role in immune protection against Tuberculosis. Owing to its great potential to increase immune response, chitosan can be considered as a suitable biodegradable polymer for intranasal administration. Methods The physiochemical properties of the nanoparticle were measured in vitro. Two weeks after the last intranasal administration, blood samples were collected and specific IgG, IFN-gama, and IL-4 levels were measured by ELISA. Results Chitosan nanoparticles containing ESAT-6 demonstrated stronger ability to induce IFN-gama, IL-4, and IgG antibody level than the control groups. Conclusion Administration of chitosan nanoparticles can be a suitable method to induce more appropriate immune responses against low inherent immunogenic tuberculosis proteins through intranasal routs.

Entities:  

Keywords:  Chitosan; ESAT-6; Mycobacterium tuberculosis; cytokines; immune responses

Mesh:

Substances:

Year:  2016        PMID: 26924121     DOI: 10.3109/21691401.2016.1146735

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  4 in total

Review 1.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

2.  Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.

Authors:  Melika Haghighi; Akbar Khorasani; Pegah Karimi; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

3.  A novel nanomicelle composed from PEGylated TB di-peptide could be successfully used as a BCG booster.

Authors:  Zohreh Firouzi; Mahmoud Reza Jaafari; Mojtaba Sankian; Sirwan Zare; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2022-02       Impact factor: 2.532

Review 4.  Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants.

Authors:  Ana Rita Franco; Francesco Peri
Journal:  Cells       Date:  2021-01-05       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.